SEARCH OUR PAGES

Products

Products

Our pipeline
Delivering first-in-class immunotherapies
of activation and regulation

OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.

We have already developed several first-in-class products that activate or regulate the immune system and cover a wide range of clinical indications, generating several academic and pharma partnerships.

OSE Immunotherapeutics’ pipeline is currently comprised of six developmental projects, four in immuno-oncology and two in autoimmune diseases. Five of our candidates are currently in the clinic.

Program
Indication
Humanized
lead
Pre-Clinical
POC
Phase 1
Phase 2
Phase 3
Partners
Immuno-oncology
Tedopi®
Neo-Epitopes
NSCLC
EU-US-lsr
Tedopi®
Neo-Epitopes
Advanced pancreatic
Early 2019 Combo with PD1
OSE-172
SIRP-α
Various cancers
Q1 2019
OSE-703
IL-7 R
Various cancers
2019

Program

  • Indication NSCLC
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2
  • Phase 3 EU-US-lsr
  • Partners
  • Indication Advanced pancreatic
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Early 2019 Combo with PD1
  • Phase 3
  • Partners
  • Indication Various cancers
  • Humanized
  • Pre-Clinical POC
  • Phase 1 Q1 2019
  • Phase 2
  • Phase 3
  • Partners
  • Indication Various cancers
  • Humanized
  • Pre-Clinical POC 2019
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
Program
Indication
Humanized
lead
Pre-Clinical
POC
Phase 1
Phase 2
Phase 3
Partners
Auto-immune diseases
FR104
CD-28
Rheumatoid
arthritis
2019
OSE-127
IL-7 R
UC Sjögren
2018

Program

  • Indication Rheumatoid
    arthritis
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 2019
  • Phase 3
  • Partners
  • Indication UC Sjögren
  • Humanized
  • Pre-Clinical POC
  • Phase 1 2018
  • Phase 2
  • Phase 3
  • Partners